Homepage Top Section1

The phase 3 Keynote-181 study assessing Keytruda as monotherapy in the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma has achieved a primary endpoint of

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common

New investors HBM Healthcare Investments (Cayman) and Nextech Invest also took part in the mezzanine financing, said TP Therapeutics. The new capital secured by the clinical-stage precision oncology

As per terms of the deal, Novartis will purchase all outstanding shares of Endocyte common stock by paying $24 per share. Through using drug conjugation technology, Endocyte will

While Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, COM701 is an investigational anti-PVRIG antibody. Apart from the clinical trial collaboration, Bristol-Myers Squibb has agreed to make

Empagliflozin was evaluated for its efficacy, safety and tolerability as an adjunctive to insulin in comparison to placebo in the late-stage clinical program, dubbed EASE. The primary efficacy

Durvalumab reduced the risk of death by 32% in comparison to standard of care in the late-stage trial. In the durvalumab arm, the median time to death or

Farxiga was assessed in a trial, dubbed DECLARE-TIMI 58, in more than 17,000 T2D adult patients having multiple CV risk factors or established CV condition. In the five-year

The approval of Hulio is based on adoption of positive opinion by the Committee for Medicinal Products for Human Use (CHMP). The CHMP determined that development program, including